Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01898130 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy
A Phase 2 study of Metastatic Cancer and Unspecified Adult Solid Tumor, Protocol Specific, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 4
- Study locations
NCT01898130: Completed Phase 2 study of Metastatic Cancer and Unspecified Adult Solid Tumor, Protocol Specific, sponsored by Northwestern University.
NCT01898130 is a Phase 2 study of Metastatic Cancer and Unspecified Adult Solid Tumor, Protocol Specific that has completed, run by Northwestern University. The registered enrollment target is 27 participants, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01898130, a Phase 2 study of Metastatic Cancer and Unspecified Adult Solid Tumor, Protocol Specific, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a study to evaluate a drug called bevacizumab in patients with cancer whose disease has spread to their brain. This study will not evaluate the effect of bevacizumab on the systemic solid tumor cancer. Bevacizumab is a medication and it is thought that bevacizumab may interfere with the growth of new blood vessels; therefore it might stop tumor growth and possibly shrink the tumor by keeping it from receiving nutrients and oxygen supplied by the blood vessels.
Primary Outcome
Radiographic Response to treatment will be assessed prior to every odd-numbered cycle using CT or MRI scans until disease progression, unacceptable toxicity as assessed by the Response Assessment in Neuro-Oncology (RANO) Criteria for target lesions. Response is defined as the number of patients with Complete Response (CR) plus those with Partial Response (PR) radiographically. Generally CR is defined as the disappearance of all target lesions and PR is defined as \>=50% decrease in the sum of th
Conditions Studied
Interventions
- PROCEDURE quality-of-life assessment
- BIOLOGICAL bevacizumab
Study Locations (4)
Illinois
- Northwestern University - Chicago
- Northwestern Memorial Hospital: Lake Forest Hospital - Lake Forest
- Cadence Health - CDH - Warrenville
New York
- Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2013-11-27 |
| Est. Completion | 2018-09-05 |
| Phase | Phase 2 |
What the finished NCT01898130 record still lists
NCT01898130 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which quality-of-life assessment is the first listed.
NCT01898130 reports a single indexed study location in Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT01898130 about?
NCT01898130 is a clinical study titled "Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy". This is a study to evaluate a drug called bevacizumab in patients with cancer whose disease has spread to their brain. This study will not evaluate the effect of bevacizumab on the systemic solid tumor cancer. Bevacizumab is a medication and it is thought that bevacizumab may interfere with the grow...
What is the current status of trial NCT01898130?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2013-11-27. Estimated completion is 2018-09-05.
What conditions does trial NCT01898130 study?
This clinical trial studies the following conditions: Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific.
What interventions are being tested in trial NCT01898130?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01898130?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01898130 being conducted?
This trial has 4 study locations across Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01898130's enrollment target sits among peer trials
27 86th of 109 higher than 24 of 109 other Metastatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Biomarkers to Detect Endocrine Therapy Resistance
RECRUITING · Phase 2
-
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
RECRUITING · Phase 2
-
Definitive Radiation for High-Risk Spine Metastases
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI